Gilead Sciences Inc (GILD)

[Tamtam]

This drug should run hard this week. hopefuly

[waqy1]

https://www.google.com/amp/s/www.fool.com/amp/investing/2020/10/30/2-no-brainer-dividend-stocks-yielding-more-than-4/

[waqy1]

Read this!!

https://www.google.com/amp/s/www.fool.com/amp/investing/2020/10/31/as-coronavirus-cases-climb-heres-1-stock-to-buy-an/

[ezyE]

This drug should run hard this week.
The only thing we got at the moment.
It's about taking it early .

[Tamtam]

Agree .Remdesivir should be tested in combination with Brilacidin ASAP

[georgejjl]

Latest Covid-19 Wave Worries Hospitals Even With New Treatments

https://www.msn.com/en-us/health/medical/latest-covid-19-wave-worries-hospitals-even-with-new-treatments/ar-BB1ayiaa?li=BBnb7Kz

Remdesivir should be tested in combination with Brilacidin ASAP

Brilacidin in combination with Remdesivir, compared to Remdesivir-only treated conditions, showed a statistically significant and synergistic inhibition of SARS-CoV-2. Of particular note, overall viral load was reduced by 99.85 percent in one combination experiment, with remaining virus dropping to near undetectable levels.

http://www.ipharminc.com/press-release/2020/9/15/laboratory-testing-of-brilacidin-for-covid-19-in-combination-with-remdesivir-reduces-viral-load-by-nearly-100-percent?rq=99

Good luck and GOD bless,

[waqy1]

I wish there was a thumbs up selection on all these posts. You would have about 1 billion!

[Mark102]

A Trump Win and back to 65.... 90 by next earnings IMO

[lojack]

https://www.fiercepharma.com/marketing/remdesivir-sales-hit-873m-as-gilead-gets-defensive-against-who-data-covid-19-drug
-GILD

[Ultimate01]

Boom! Gilead better partner up!


http://www.ipharminc.com/new-blog/2020/10/30/preprint-brilacidin-a-covid-19-drug-candidate-exhibits-potent-in-vitro-antiviral-activity-against-sars-cov-2

[georgejjl]

The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug

https://www.sciencemag.org/news/2020/10/very-very-bad-look-remdesivir-first-fda-approved-covid-19-drug

*************************************************************

Remdesivir should be tested in combination with Brilacidin ASAP

Quote:
Brilacidin in combination with Remdesivir, compared to Remdesivir-only treated conditions, showed a statistically significant and synergistic inhibition of SARS-CoV-2. Of particular note, overall viral load was reduced by 99.85 percent in one combination experiment, with remaining virus dropping to near undetectable levels.


http://www.ipharminc.com/press-release/2020/9/15/laboratory-testing-of-brilacidin-for-covid-19-in-combination-with-remdesivir-reduces-viral-load-by-nearly-100-percent?rq=99

Good luck and GOD bless,

[BottomBounce]

$GILD ER was beautiful

[waqy1]

https://www.google.com/amp/s/amp.ft.com/content/92918d20-11ad-405b-91b6-412cc12704a0

[Lucky_Charm$]

Not good huh?

[Ultimate01]

https://www.reuters.com/article/us-gilead-sciences-results-idUSKBN27D2ZJ

[BottomBounce]

COVID Measures Will Not End When Vaccine Arrives, Experts Say
https://learningenglish.voanews.com/a/covid-measures-will-not-end-when-vaccine-arrives-experts-say/5637845.html $GILD

[BottomBounce]

$GILD One in Three Americans Would Not Get COVID-19 Vaccine
https://news.gallup.com/poll/317018/one-three-americans-not-covid-vaccine.aspx

[BottomBounce]

$GILD U.S. Public Now Divided Over Whether To Get COVID-19 Vaccine
https://www.pewresearch.org/science/2020/09/17/u-s-public-now-divided-over-whether-to-get-covid-19-vaccine/

[BottomBounce]

Attempts At Herd Immunity Not Working In Sweden, Evidence Shows
https://khn.org/morning-breakout/attempts-at-herd-immunity-not-working-in-sweden-evidence-shows/ $GILD

[BottomBounce]

Americans calling for herd immunity should look at Sweden's coronavirus experiment to see why it won't work
https://www.businessinsider.com/americans-call-herd-immunity-sweden-experiment-coronavirus-not-working-2020-5 $GILD

[georgejjl]

Vaccine hopes rise as Oxford jab prompts immune response among old as well as young adults

https://in.reuters.com/article/health-coronavirus-astrazeneca-vaccine/vaccine-hopes-rise-as-oxford-jab-prompts-immune-response-among-old-as-well-as-young-adults-idUSKBN27B0J1

That is a strong vaccine response.

*************************************************************

Remdesivir should be tested in combination with Brilacidin ASAP

Brilacidin in combination with Remdesivir, compared to Remdesivir-only treated conditions, showed a statistically significant and synergistic inhibition of SARS-CoV-2. Of particular note, overall viral load was reduced by 99.85 percent in one combination experiment, with remaining virus dropping to near undetectable levels.

http://www.ipharminc.com/press-release/2020/9/15/laboratory-testing-of-brilacidin-for-covid-19-in-combination-with-remdesivir-reduces-viral-load-by-nearly-100-percent?rq=99

Good luck and GOD bless,

[BottomBounce]

$gild Herd immunity won’t solve America’s COVID-19 problem
https://theconversation.com/herd-immunity-wont-solve-americas-covid-19-problem-139724

[BottomBounce]

“Herd Immunity” is Not an Answer to a Pandemic
https://www.idsociety.org/news--publications-new/articles/2020/herd-immunity-is-not-an-answer-to-a-pandemic/

[lojack]

They say a vaccine may never happen since it deals with the respiratory system..
-GILD

[BottomBounce]

A 'herd mentality' can’t stop the COVID-19 pandemic. Neither can a weak vaccine.
https://www.nationalgeographic.com/science/2020/10/natural-herd-immunity-mentality-cannot-stop-coronavirus-weak-vaccine-cvd/

[BottomBounce]

COVID-19 Story Tip: Herd Immunity Is a Dangerous Strategy for Fighting COVID-19, Says Johns Hopkins Expert
https://www.hopkinsmedicine.org/news/newsroom/news-releases/herd-immunity-is-a-dangerous-strategy-for-fighting-covid-19-says-johns-hopkins-expert

[BottomBounce]

U.S. reports a record 500,000 new cases in the past week $GILD
https://www.nytimes.com/live/2020/10/28/world/covid-19-coronavirus-updates

[BottomBounce]

A 46 percent spike in Covid-19 patients strains the capacities of hospitals in the U.S.

https://www.nytimes.com/live/2020/10/28/world/covid-19-coronavirus-updates

[BottomBounce]

Why North and South Dakota are suffering the worst Covid-19 epidemics in the US
https://www.vox.com/future-perfect/2020/10/27/21534480/north-dakota-south-dakota-covid-coronavirus-pandemic-third-wave

[BottomBounce]

$GILD Gilead sold $873 million worth of its antiviral COVID-19 treatment https://www.gilead.com/news-and-press/press-room/press-releases/2020/10/us-food-and-drug-administration-approves-gileads-antiviral-veklury-remdesivir-for-treatment-of-covid19

[lojack]

I almost sold another position to buy more.. But as of right now I’m all in at a $62 average. Didn’t think it would get to this pps but hey, as long as we are headed north we should be good! Good luck to you!
-GILD

[Purple Wonder]

Sadly politics even affect companies doing what they can to help solve a worldwide issue. Locked and loaded and looking for decent returns in the near term.

[waqy1]

It is because It helped President Trump. The powers that be are obviously messing with price. Have patience. Once these fools are done playing around it will go back up where it is supposed to be. Strong buy and Strong hold if you are in already. IMHO

[Purple Wonder]

Trading down after beating market expectations and future Remdesevir sales going to increase given the current worldwide spike of Covid cases. Shake and bake I guess.

[Purple Wonder]

Good earnings report and the Remdesivir sales are going to get a lot bigger as this quarter only captured sales made mostly to the US. Looks like games are being played with the price now rather than fundamental trading.

[BottomBounce]

$GILD Gilead (GILD) reported third-quarter earnings of $360 million, or 29 cents a share, on revenue of $6.58 billion, up from $5.6 billion a year ago

[BottomBounce]

Earning REPORT $gild Gilead reported sales of $873 million for Veklury, its COVID-19 treatment previously known as remdesivir, beating expectations.

[BottomBounce]

Earning REPORT $gild Gilead reported sales of $873 million for Veklury, its COVID-19 treatment previously known as remdesivir, beating expectations.

[BottomBounce]

Nice entry

[BottomBounce]

*** $GILD https://twitter.com/OfficialMining/status/1321475260437483520

[BottomBounce]

$GILD The antiviral drug remdesivir is the first and only drug approved for COVID-19 treatment in the U.S. https://www.app.com/videos/news/2020/10/23/remdesivir-approved-fda-treatment-covid-19-patients/3736159001/

[BottomBounce]

Loading Zone $GILD

[waqy1]

How can Gilead be at 52 week low with news?? I bet these research analysts have a stake in beating down stock prices just before earnings because they know it will pop by the next day.

[Ultimate01]

Looks like Lilly will take a slice of the pie.


https://investor.lilly.com/news-releases/news-release-details/lilly-announces-agreement-us-government-supply-300000-vials?fbclid=IwAR0WDohiOBccubYR8nSAVNyiwK9mXBhA9P6N7ksHfIoVsQDHZNK7I2WEdMw

[lojack]

Nobody is even talking about the company that Gilead just bought out to make them not only an HIV powerhouse but a cancer powerhouse as well!
https://www.gilead.com/news-and-press/press-room/press-releases/2020/10/gilead-sciences-completes-acquisition-of-immunomedics-inc
Forget Covid 19 even though Gilead also makes the only drug approved by the FDA to shorten its span and help your immune system fight it to where it doesn’t kill you! Oh yeah and how about this to add to them financials coming out in less than 2 days...
https://www.google.com/amp/s/mobile.reuters.com/article/amp/idUSKBN26Y25K
-GILD

[lojack]

Nice post

[lojack]

First sentence in the first paragraph of your article states:
Mexico will not necessarily follow the U.S. Food and Drug Administration (FDA) in approving Gilead Science Inc's antiviral drug remdesivir for use in COVID-19 patients, a top Mexican health official said on Friday.

“Will not necessarily”. LMFAO- WHO did a bs study to and then what happened? FDA approval!
Better get in before this jumps over a hundred pps easy after financials come out and real facts come out about the drug helping so many people since everyone is been ok’d to get it per FDA!
-GILD

[lojack]

Boom! Nice find! Here is an article as well.
https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/buy-gilead-gild-ahead-earnings-123712869.html
-GILD

[EJEW]

Zacks Equity Research
Published Oct 27, 2020 11:29 AM EDT

Moderna, Inc. MRNA is scheduled to report third-quarter 2020 results on Oct 29, before market open. In the last reported quarter, the company delivered an earnings surprise of 13.89%.

The company’s earnings beat the Zacks Consensus Estimate in each of the last four quarters with the average surprise being 11.8%.

Moderna’s share price has surged 259.1% so far this year against the industry’s decrease of 3.1%.

Factors to Note

Moderna has no marketed products in its portfolio. On the third-quarter earnings call, investor focus will likely remain on the progress of Moderna’s pipeline candidates, especially its coronavirus vaccine candidate.

The company has been actively engaged in developing its coronavirus vaccine — mRNA-1273. It is one of the leading players in this field with phase III study — COVE — initiated in July. The company is conducting the study in collaboration with the National Institute of Allergy and Infectious Diseases. Interim data from a phase I study evaluating mRNA-1273, announced in September, had shown rapid and strong immune responses against SARS-CoV-2 in elderly patients aged 56 or above. The candidate is well tolerated in this patient population.

Moreover, Moderna completed enrollment in the COVE study last week. Among total patient population of 30,000 in the study, 25,650 participants received their second vaccination as of Oct 22. We expect the company to provide an update on the COVE study on its third-quarter earnings call. Investors will likely focus on any update on timeline for filing for emergency use authorization for the candidate on the call.

In July, the company received additional commitment for funding of up to $472 million from the Biomedical Advanced Research and Development Authority (“BARDA”) to support late-stage clinical development of the vaccine. The company had earlier received a funding commitment of up to $483 million from BARDA. These funding commitments are likely to have boosted revenues and offset the company’s rising operating expenses, primarily to support development and commercialization of mRNA-1273.

Apart from mRNA-1273, Moderna is developing several other mRNA-based products targeting different indications including cancer. The company also has collaborations under which its partners like AstraZeneca AZN and Merck use its mRNA technology for development of therapies targeting different indications. The partners pay milestone payments to Moderna, which comprise its total revenues. These collaborations revenues can vary every quarter. The Zacks Consensus Estimate for collaboration revenues for the third quarter is pegged at $16.76 million.

In September, Moderna inked a new three-year research collaboration with its existing partner, Vertex Pharmaceuticals VRTX, for discovering and optimization of novel LNPs and mRNAs that can deliver gene-editing therapies for treating cystic fibrosis. Modern also signed another collaboration agreement with Italy-based Chiesi Farmaceutici for developing potential pulmonary arterial hypertensiontherapeutics in the same month. Upfront payments from these two deals are likely to have boosted revenues in the third quarter.
Earnings Whispers

Our proven model does not conclusively predict an earnings beat for Moderna this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (loss of 95 cents per share) and the Zacks Consensus Estimate (loss of 43 cents per share), is -123.16%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter

Zacks Rank: Moderna currently has a Zacks Rank #2.

[BottomBounce]

$60+ coming strong $GILD